Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein
- 1 July 2004
- journal article
- Published by Elsevier in Kidney International
- Vol. 66 (1) , 338-347
- https://doi.org/10.1111/j.1523-1755.2004.00736.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese ratsKidney International, 2003
- The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremiaKidney International, 2002
- End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?Kidney International, 2001
- Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patientsKidney International, 2000
- Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failureKidney International, 1999
- Inflammation enhances cardiovascular risk and mortality in hemodialysis patientsKidney International, 1999
- Alterations in nonenzymatic biochemistry in uremia: Origin and significance of “carbonyl stress” in long-term uremic complicationsKidney International, 1999
- Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.Journal of Clinical Investigation, 1997
- The Advanced Glycation End Product, N∊-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation ReactionsJournal of Biological Chemistry, 1996
- New biomarkers of Maillard reaction damage to proteinsNephrology Dialysis Transplantation, 1996